|
|
CHI's Structure-Based Drug Design
概要
GPCR的構造模擬
蛋白質交互作用位置之解析
電腦模擬蛋白質設計
有效活性化合物(hits)及先導化合物(lead)之優化
配體結合(ligand binding)中受體彈性之分析
嵌合(docking)與篩選(screening)的挑戰
実験成果
案例學習
相關活動
在Structure-Based Drug Design 國際會議召開前,於同一場所另有一個
Protein Kinase Targets國際會議 ,在此建議一併註冊參加。
預定發表主題
- AILERON Therapeutics
- ARIAD Pharmaceuticals Inc.
- AstraZeneca R&D Mölndal
- Bristol-Myers Squibb
- California Institute of Technology
- Centocor Research and Development
- Chemical Computing Group Inc.
- Elan Pharmaceuticals
- Harvard Medical School
- Locus Pharmaceuticals
- Lundbeck Research (Denmark) Merck Research Laboratories
- National Center for Scientifi c Research
(CNRS)
- NIH, NIDDK
- Novartis
- OSI Pharmaceuticals
- Pfizer Global Research and Development
- Schrodinger, Inc.
- SGX Pharmaceuticals
- SimBioSys
- University of York
- Vernalis
|
語言選擇
|